Squamous cell carcinoma of head and neck

68 clinical trials

Quick filters

Clinical trials for Squamous cell carcinoma of head and neck

68 trials across Europe

See all trials →

Quick filters

68 Clinical trials

Squamous cell carcinoma of head and neck

Recruiting

Registered drug

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

Study of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Rakuten Medical Inc.

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

Study of nivolumab and ipilimumab immunotherapy for organ preservation in patients with advanced head and neck squamous cell carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Ivonescimab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Janssen Cilag International

Contact Research Centre

See all trials →

Squamous cell carcinoma of head and neck

Clinical trials for Squamous cell carcinoma of head and neck

Squamous cell carcinoma of head and neck

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Squamous cell carcinoma of head and neck

Study of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases

Squamous cell carcinoma of head and neck

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Squamous cell carcinoma of head and neck

Study of nivolumab and ipilimumab immunotherapy for organ preservation in patients with advanced head and neck squamous cell carcinoma

Squamous cell carcinoma of head and neck

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Squamous cell carcinoma of head and neck

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.